Considering that current therapies and clinical trials are focussed on targeting specific and relevant pathways in GBM physiopathology, including the use of TGF-β inhibitors in gliomas (e.g., NCT01582269, NCT01682187) [90, 91], we speculate that combining TGF-β inhibitors and SSAs might be a potential therapeutic approach worth to be tested in specific subsets of GBM patients. Here, TGFB1 is linked to glioma.